Can an NTI-tss device be effective as a first-line therapy in patients with TMD myofascial pain?

Abstract

Objectives

This study was conducted to evaluate if integrating a nociceptive trigeminal inhibition–tension suppression system (NTI-tss) device with first-line therapy of myofascial pain, which includes guidance, assurance, counseling, and behavioral changes, would be more effective in alleviating symptoms.

Methods

This randomized controlled clinical trial included 40 patients who were clinically diagnosed with myofascial pain according to Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD). Patients were randomly divided into 2 groups: the first group comprised patients who received guidance, assurance, counseling, and behavioral changes; an NTI-tss device was integrated to this protocol in the second group.

Results

Both groups exhibited reduction in pain levels and improvement of jaw function compared with baseline values, but the difference was not significant.

Conclusion

Both groups demonstrated improvements in 6 weeks; however, the integration of NTI-tss device into the therapy protocol did not provide any additional benefit in relieving symptoms of myofascial pain.

This article is protected by copyright. All rights reserved.

http://ift.tt/2rvrobv